SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis - Top_Thought_Leaders - MDSpire

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation

  • By

  • Henry Thomas

  • March 10, 2026

  • 2 min

Share

Top Thought Leaders in Pathology

Brief introduction explaining scope and methodology.

Original Source(s)

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

  • by Henry Thomas

  • March 10, 2026

Related Content

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Sex differences in iron stores and associations of body iron with cardiovascular risk factors in the middle-aged general population

Association Between Metabolic Clusters and Microbial Age in High-Risk Populations for Diabetes and Their Potential Impact on Cardiovascular Disease Risk: Cross-Sectional Observational Study